Belite Bio (BLTE) Stock Price, News & Analysis

Company Overview

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Key Stats

• Today's Range: $64.50 to $65.62
• 50-Day Range: $54.10 to $67.29
• 52-Week Range: $43.70 to $86.53
• Volume: 10,940 shs
• Average Volume: 48,781 shs
• Market Capitalization: $2.09 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $96.67
• Consensus Rating: Buy

Belite Bio Stock Analysis - MarketRank™

Belite Bio scored higher than 44% of companies evaluated by MarketBeat, and ranked 649th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Belite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Belite Bio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Belite Bio are expected to grow in the coming year, from ($1.17) to ($0.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Belite Bio is -59.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Belite Bio is -59.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Belite Bio has a P/B Ratio of 19.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.32% of the float of Belite Bio has been sold short.

Short Interest Ratio / Days to Cover

Belite Bio has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Belite Bio has recently increased by 23.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Belite Bio does not currently pay a dividend.

Dividend Growth

Belite Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.32% of the float of Belite Bio has been sold short.

Short Interest Ratio / Days to Cover

Belite Bio has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Belite Bio has recently increased by 23.05%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.74

News Sentiment

Belite Bio has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Belite Bio this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Belite Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.53% of the stock of Belite Bio is held by institutions.

BLTE Stock Analysis - Frequently Asked Questions

How have BLTE shares performed this year?

Belite Bio's stock was trading at $63.10 at the beginning of the year. Since then, BLTE shares have increased by 3.8% and is now trading at $65.50.
View the best growth stocks for 2025 here.

How were Belite Bio's earnings last quarter?

Belite Bio, Inc (NASDAQ:BLTE) released its quarterly earnings data on Monday, March, 17th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02.
Read the conference call transcript.

When did Belite Bio IPO?

Belite Bio (BLTE) raised $36 million in an initial public offering on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share.

Who are Belite Bio's major shareholders?

Belite Bio's top institutional shareholders include GAMMA Investing LLC (0.38%), Alyeska Investment Group L.P. (0.26%) and GAMMA Investing LLC (0.01%).

How do I buy shares of Belite Bio?

Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Belite Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Belite Bio investors own include Paycom Software (PAYC), Centrus Energy (LEU), Planet Labs PBC (PL), uniQure (QURE), Grayscale Ethereum Trust (ETH) (ETHE), Marathon Oil (MRO) and Vale (VALE).

Company Calendar

• Last Earnings: 3/17/2025
• Today: 5/30/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BLTE
• CIK: 1889109
• Web: belitebio.com
• Phone: 858-246-6240
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $96.67
• High Stock Price Target: $110.00
• Low Stock Price Target: $80.00
• Potential Upside/Downside: +47.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -31.94%
• Return on Assets: -30.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 30.73
• Quick Ratio: 30.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.28 per share
• Price / Book: 19.97

Miscellaneous

• Outstanding Shares: 31,838,000
• Free Float: 27,607,000
• Market Cap: $2.09 billion
• Optionable: Not Optionable
• Beta: -1.48